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Objective: This study was designed to investigate the feasibility of and potential
functional improvement with embryonic stem cell transplantation in rats 32 weeks
after myocardial infarction.
Methods: Before cell transplantation, cultured embryonic stem cells were trans-
fected with the complementary DNA of green fluorescent protein to identify
engrafted cells in myocardium. Myocardial infarction was induced by ligation of the
left coronary artery. Either 3  105 mouse embryonic stem cells or an equivalent
volume of cell-free medium was injected into injured myocardium within 20
minutes after induction of myocardial infarction.
Results: Embryonic stem cell transplantation significantly increased the survival rate
in rats undergoing myocardial infarction during the experimental period of 32
weeks. Hemodynamic and echocardiographic data showed that embryonic stem cell
transplantation significantly improved ventricular function relative to the myocar-
dial infarction plus medium control group. Tissue positive for green fluorescent
protein was found in the injured myocardium with cell transplantation. The propor-
tion of myocardium positively immunostained by antibodies against -myosin
heavy chain and cardiac troponin I was greater in the infarcted area with embryonic
stem cell transplantation than in the injured myocardium with medium injection.
Single green fluorescent protein-positive cells with a rod shape and clear striations
were observed in cardiomyocytes isolated from infarcted hearts with embryonic
stem cell transplantation. In addition, the number of blood vessels in injured
myocardium was greater in the cell-transplanted myocardial infarction group than in
the medium-injected myocardial infarction group.
Conclusions: Engrafted embryonic stem cells differentiated into cardiomyocytes in
injured myocardium, caused an angiogenetic effect, and subsequently improved
cardiac function during the 32-week observation period.
Heart failure, which may be the consequence of acute myocardialinfarction (MI), is one of the major medical problems facingdeveloped countries. Permanent loss of cardiomyocytes and non-functional fibrous scar formation after MI result in irreversibledamage of cardiac function. Medical interventions can result inalleviation of the symptoms of cardiac dysfunction in patients
with MI. Because a significant percentage of patients have progression to severe
heart failure despite medical treatment, however, new and novel therapeutic ap-
proaches are always critical and interesting. Heart transplantation is an acceptable
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therapy for end-stage heart failure, but long-term results
have been limited by recurrent episodes of rejection and the
development of transplanted coronary arteriopathy. The
number of patients being listed for heart transplantation
continues to escalate, whereas the number of available do-
nors remains relatively unchanged.1 Only a small percent-
age of patients receive heart transplants because of this
shortage of donors. New and effective therapies for patients
with heart failure are therefore urgently required.
Recent studies have demonstrated that transplantation of
cultured cells into damaged myocardium offers a new ap-
proach to restoration of the impaired cardiac function in
either cryoinjured2,3 or infarcted hearts.4-9 Engrafted cells
have been shown to survive, proliferate, and form gap
junctions with the host myocardium.7,10 In contrast, Wa-
tanabe and colleagues11 found that fetal and neonatal pig
cardiomyocytes and the cardiac-derived cell line HL-1 did
not survive after grafting into infarcted pig myocardium.
However, a recent study in mice showed that intramyocar-
dial transplantation of bone marrow cells not only generated
new myocardium but also significantly improved left ven-
tricular (LV) function.4 The underlying mechanism of these
discrepancies may result from differences in the types of
donor cells or the status of the host myocardium at the time
of cell transplantation.
Embryonic stem cells, pluripotent cells containing the
capacity for unlimited in vitro proliferation, may be useful
to cardiogenesis.12 Our recent study showed that embryonic
stem cell transplantation was feasible in injured myocar-
dium and improved cardiac function in rats with MI 6 weeks
after transplantation.13 However, the prolonged effects of
embryonic stem cell transplantation on postinfarction fail-
ing hearts remain to be determined. It is therefore important
to know whether the beneficial effects of cell transplantation
could last for a longer period. This study investigated the
effects of embryonic stem cell transplantation on mortality
and cardiac function in rats 32 weeks after MI induction and
cell implantation.
Material and Methods
Embryonic Stem Cell Preparation for Transplantation
The mouse embryonic stem cell line ES-D3 (American Type
Culture Collection, Manassas, Va) was maintained and cultured by
the methods previously described.14 Briefly, ES-D3 cells were
cultured in Dulbecco modified Eagle medium on mitotically inac-
tive mouse embryonic fibroblast feeder cells (American Type
Culture Collection). The medium was supplemented with 15%
fetal bovine serum, 0.1-mmol/L -mercaptoethanol (Sigma, St
Louis, Mo), and 103 U/mL of leukemia inhibitory factor-condi-
tioned medium (Life Technologies, Inc, Rockville, Md) to sup-
press differentiation. To initiate differentiation, embryonic stem
cells were dispersed with trypsin and resuspended in the medium
without supplemental leukemia inhibitory factor and cultured with
the hanging drops method (approximately 400 cells per 20 L) for
5 days. They were then seeded into 100-mm cell culture dishes.
Beating cardiomyogenic clusters were dissected by use of a sterile
micropipette and recultured for another 2 days at 37°C in a 98%
humidified atmosphere with 5% carbon dioxide. Action potentials
recorded in 2-week cultured beating embryonic stem cells (data
not shown) were similar to those in cultured neonatal mouse
cardiomyocytes.13
Before transplantation, cells dissected from beating clusters
were transfected with green fluorescent protein (GFP), a marker
for identification of engrafted cells from host myocytes in injured
myocardium. Plasmids with an immediate-early (IE) gene of hu-
man cytomegalovirus (CMV) promoter-enhancer driving GFP
gene (5.7 kb) and Gene PORTER transfection reagent were ob-
tained from Gene Therapy Systems Inc (San Diego, Calif). Em-
bryonic stem cells (2 105 cells) were plated onto 100-mm dishes
and were grown to 50% to 60% confluence on the day of trans-
fection. The GFP transfection efficiency, as detected under fluo-
rescent microscopy, was more than 90%. Two days after GFP
transfection, cultured embryonic stem cells were digested with
trypsin and resuspended in Joklik modified medium (Sigma) with
a density of 107 cells/mL for cell transplantation. We observed
under microscopy that about 40% to 50% of the cells used for
transplantation were beating. In addition, after 11 days of culture
by the hanging drops method without micropipette dissection of
beating cells, flow cytometry revealed that 26%  1.2% (mean 
SEM, n  5 runs) of embryonic stem cells were positive for
cardiac -myosin heavy chain (-MHC).
Experimental Myocardial Infarction and Embryonic
Stem Cell Transplantation
Experiments were performed in male Wistar rats (Charles River
Laboratories, Inc, Wilmington, Mass) with an initial body weight
of approximately 300 g. The investigation conformed to the Guide
for the Care and Use of Laboratory Animals prepared by the
Institute of Laboratory Animal Resources, National Research
Council, and published by the National Academy Press, revised
1996 (NIH Publication No. 85-23). The protocol was approved by
our institutional animal care committee. MI was created by ligation
of the left coronary artery as previously described elsewhere.15
Within 20 minutes after MI induction, 3  105 embryonic stem
cells in 30 L medium were injected with a tuberculin syringe into
three different sites in infarcted hearts. Two injection sites were at
the border of the ischemic area, and the other was in the middle of
the injured area. The number of embryonic stem cells injected here
was in the range (30,000 to 500,000 cells/animal) transplanted by
other researchers in animals after MI.4 Control rats with MI
received the exact volume of the cell-free medium as received by
the rats treated with embryonic stem cell transplantation. No
experimental rats were treated with immunosuppressants during
the 32-week follow-up, despite the xenogenic cell transplantation.
Survivals were evaluated in all groups during the 32-week
follow-up. The study comprised of the following groups: rats with
MI that received transplanted embryonic stem cells (MI plus
embryonic stem cells, n  26), control rats with MI injected with
an exact volume of the cell-free medium (MI plus medium, n 
31), and a sham operation control group with neither ligation of the
coronary artery nor intramyocardial injection (sham control, n 
23).
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Echocardiographic Study
Thirty-two weeks after transplantation, the animals (5 for each
group) were anesthetized with pentobarbital. The echocardio-
graphic procedure was performed as previously described else-
where.16 A commercially available echocardiographic system
equipped with a 12.5-MHZ probe (Agilent Sonos 5500; Agilent
Technologies, Palo Alto, Calif) was used in our experiments.
Initially, a 2-dimensional short-axis view of the LV was obtained
at the level of the papillary muscles. After optimizing gain settings
and ensuring that the image was on axis, M-mode tracings were
recorded through the anterior and posterior LV walls at a paper
speed of 100 mm/s. This orientation was chosen to allow delinea-
tion of wall thickness and motion in infarcted and noninfarcted
territories. The results were recorded on optical disks, and the
M-mode tracings were analyzed. LV mass was calculated with a
cube formula. Relative anterior wall thickness, relative posterior
wall thickness, and LV internal dimensions were measured from at
least three consecutive cardiac cycles. We also used endocardial
fractional shortening and midwall fractional shortening as indices
to estimate LV systolic function.
Measurement of Hemodynamics
In another series of experiments, rats (n 8 in sham control group,
n  8 in MI plus medium group, and n  9 in MI plus embryonic
stem cells group) were anesthetized again with pentobarbital at 32
weeks after MI induction and cell transplantation. Hemodynamic
measurements were performed in vivo with a modification of a
method described previously.13,16 Briefly, a carotid artery of a rat
(anesthetized by intraperitoneal administration of pentobarbital at
60 mg/kg) was isolated and cannulated with a 3F high-fidelity
microtip catheter connected to a pressure transducer (Millar In-
struments, Inc, Houston, Tex). The Millar catheter was carefully
advanced into the LV. LV systolic and end-diastolic pressures, the
maximum rate of LV systolic pressure rise (dP/dtmax), and heart
rate were monitored and recorded on a chart strip recorder. Rats
were allowed to breathe spontaneously during hemodynamic mea-
surements. After hemodynamic measurements, the rat was killed
and the heart was rapidly excised. The LV, including the septum,
was weighed and normalized for body weight. The ratio was
calculated as index of hypertrophy.
Measurement of Infarct Size, Identification of
Transplanted Cells, and Histologic Analysis
Under pentobarbital anesthesia (100 mg/kg administered intraperi-
toneally), the rats (n  11 in the sham control group, 12 in the MI
plus medium group, and 10 in the MI plus embryonic stem cells
group) were killed to evaluate morphologic characteristics and to
identify the engrafted cells. The hearts were quickly removed and
dissected into four transverse sections from apex to base. Subse-
quently, the transverse sections were embedded in tissue-freezing
medium. Partial 5-m transverse slices from each section were
prepared for hematoxylin and eosin staining, and the images were
digitized. Infarct size was calculated by dividing the sum of the
planimetered endocardial and epicardial circumferences of the
infarcted area by the sum of the total epicardial and endocardial
circumferences of the LV.17
The survival of engrafted cells was identified by GFP-positive
tissue in frozen sections made from hearts with MI. Transforma-
tion of cardiaclike cells from engrafted embryonic stem cells was
verified by antibody immunostaining for cardiac -MHC and
cardiac troponin I (TnI). Briefly, frozen tissue sections were fixed
in acetone at 4°C for 10 minutes and incubated separately with a
goat polyclonal immunoglobulin G anti-TnI antibody (Santa Cruz
Biotechnology, Inc, Santa Cruz, Calif) or a mouse anti--MHC
monoclonal antibody (Berkeley Antibody Co, Richmond, Calif)
for 60 minutes at room temperature. After washing with phos-
phate-buffered saline solution, sections were incubated with a
rabbit antigoat conjugated rhodamine immunoglobulin G for TnI
or a goat antimouse conjugated fluorescein immunoglobulin G for
-MHC (Pierce Chemical Company, Rockford, Ill). Immunostain-
ing was performed on serial sections of hearts with MI. To verify
the survival and transdifferentiation of engrafted cells, single car-
diomyocytes were enzymatically isolated from hearts (n 4) at 32
weeks after MI induction and cell transplantation. The detailed
isolation method is described in a previous report.18
Measurement of Capillary Density
The effect of embryonic stem cell transplantation on angiogenesis
was evaluated by counting the number of capillary vessels3 within
the infarcted zone from frozen sections with hematoxylin and
eosin staining under light microscopy. A capillary vessel was
defined as a vessel with a diameter less than 20 m. The number
of capillaries was counted under microscopy (400 magnification)
for five random fields in the infarcted area and presented as the
mean of blood vessels per unit area (0.2 mm2).
Data Analysis
All values are presented as mean  SE. Data collected at the end
of the 32-week follow-up period were evaluated by 1-way analysis
of variance. If analysis of variance showed a significant difference,
an unpaired Student t test was used to compare two individual
groups. Survival during the 32-week observation period was ana-
lyzed by standard Kaplan-Meier analysis, and a statistical compar-
ison between survival curves was made with the log-rank test.
Results
To evaluate the effect of embryonic stem cell transplanta-
tion on mortality in animals after MI, the survivals during
the 32-week observation period were calculated for the
three different animal groups. As Figure 1 shows, transplan-
tation of embryonic stem cells significantly increased sur-
vival rate in rats after MI. Only 3 of 26 animals in the MI
plus embryonic stem cells group (11.5%) died during the
entire experiment. In contrast, mortality was much higher
among rats with MI injected with the cell-free medium.
During the 32-week follow-up period, 7 of 31 rats in the MI
plus medium group (22.6%) died. All moribund rats showed
exertional dyspnea and decreased mobility at 6 weeks after
MI, with ascites and pleural effusions seen during necropsy.
One rat from the MI plus embryonic stem cells group and 2
from the MI plus medium group died within the first week
after MI and showed none of these signs. Kaplan-Meier
analysis (Figure 1) demonstrated a significant increase (log-
rank  3.86, P  .05) in survival in the rats transplanted
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with embryonic stem cells compared with the animals in-
jected with the cell-free medium.
Table 1 summarizes the effects of embryonic stem cell
transplantation on LV mass and infarct area in rats at 32
weeks after the MI induction and cell transplantation. LV
weight and the ratio of LV weight to body weight were
significantly increased in the MI plus medium group relative
to the sham control group. However, embryonic stem cell
transplantation significantly reduced not only the severity of
LV hypertrophy but also the area of infarction in the rats
with MI. In addition, the LV systolic pressure and maxi-
mum rising rate of pressure (dP/dtmax) were significantly
recovered in the rats transplanted with embryonic stem cells
(Figure 2) relative to the medium-injected group. The LV
end-diastolic pressure was significantly lower in the MI plus
embryonic stem cells group than in the rats injected with the
cell-free medium. There were no significant differences in
heart rate among the three groups (373  8 beats/min in
sham control group, 390 12 beats/min in MI plus medium
group, and 382  9 beats/min in MI plus embryonic stem
cells group). These results indicate that embryonic stem cell
transplantation significantly improved LV function without
an alteration of heart rate at 32 weeks after MI induction and
cell implantation.
Table 2 and Figure 3 show the results of echocardio-
graphic assessment of cardiac function in rats at 32 weeks
after MI and embryonic stem cell implantation. The LV
cavity became dilated in infarcted rat hearts with injection
of the cell-free medium. Enlargement of LV cavity dimen-
sions in infarcted hearts resulted in significant decreases in
anterior and posterior wall thicknesses and subsequently
produced reductions in endocardial and midwall fractional
shortenings. The ratio of LV mass to body weight was
significantly less at 32 weeks after MI in the rats trans-
TABLE 1. General characteristics of sham operation group
and groups with MI
Sham operation
(n  8)
MI plus
medium
(n  8)
MI plus
embryonic stem
cells
(n  9)
Body weight (g) 623.6 14.2 619.5 13.9 598.5 16.4
LV weight (mg) 978.3 9.9 1224.3 12.7* 1143.6 8.9†
LV weight/body
weight ratio
(mg/g)
1.5 0.15 2.1 0.12* 1.7 0.11
Infarct size (%) 37.2 1.5 30.6 1.1†
Values are mean  SE. Infarct size was measured in 5 rats in each group.
Animals in sham operation group were measured at 32 weeks after
operation; rats in MI groups were measured at 32 weeks after MI and
either injection with cell-free medium or embryonic stem cell transplanta-
tion.
*P  .05 versus sham operation group.
†P  .05 versus MI plus medium group.
Figure 1. Kaplan-Meier survival curves for sham control group (Sham, circles) and rats with induced MI injected
with cell-free medium (MIMedium, squares) or transplanted with embryonic stem cells (MIES Cells, triangles)
during 32-week trial. Compared with MI plus medium group, rats with MI plus embryonic stem cell transplantation
had significantly increased survival.
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planted with embryonic stem cells than in the animals that
received medium injection. The LV anterior and posterior
walls in the infarcted zone were thicker in the rats with cell
transplantation than in the rats with medium injection. In
addition, LV diastolic and systolic dimensions were de-
creased in rats with cell transplantation.
To identify the survival of engrafted cells in damaged
myocardium, fresh-frozen sections were prepared from
hearts at 32 weeks after embryonic stem cell transplantation.
Figure 4, A, shows that richly GFP-positive spots were
detected under fluorescent microscopy in myocardium with
cell implantation. Those engrafted cell spots were found
either in the middle of the infarcted zone or in the border
zone between normal and infarcted myocardium. This result
suggests that engrafted cells, or at least some proportion of
them, survived well in injured myocardium at 32 weeks
after MI induction and embryonic stem cell transplantation.
In addition, GFP-positive cells were observed in single
myocytes isolated from hearts at 32 weeks after embryonic
stem cell transplantation (Figure 4, B). These GFP-positive
cells were rod shaped with clear striations, characteristic of
adult mammalian cardiomyocytes (Figure 4, C). The aver-
age number of GFP-positive cells isolated from 4 rats after
the 32-week follow-up was 1,929,500  119,907 out of a
total average of 16,263,900  1,218,478 myocytes. The
percentage of GFP-positive cells among total isolated LV
myocytes was 11.9%, which is higher than the percentage of
GFP-positive cells in rat hearts at 6 weeks after MI and
embryonic stem cell transplantation (7.3%).13 Hematoxylin
and eosin staining of myocardial sections showed engrafted
cells in injured myocardium at 32 weeks after embryonic
stem cell transplantation (Figure 5, C). More -MHC (Fig-
Figure 2. Embryonic stem cell transplantation significantly improved LV function in rats after MI. A, LV systolic
pressure (LVSP); B, LV end-diastolic pressure (LVEDP); C, rate of peak LV systolic pressure rise (dP/dtmax).
Measurements were conducted 32 weeks after MI induction. Sham, Sham operation group (n  10); MIMedium,
rats with MI injected with cell-free medium (n  9); MIES Cells, rats with MI transplanted with embryonic stem
cells (n  10). Asterisk indicates P < .05 versus sham control; double asterisk indicates P < .01, versus sham
control; crosshatch indicates P < .05 versus MI plus medium.
TABLE 2. Echocardiographic measurement of LV function in vivo
Sham operation
(n  8)
MI plus medium
(n  8)
MI plus
embryonic stem
cells (n  9)
Posterior wall thickness (%) 79.2 8.5 46.2 3.5* 59.5 4†‡
Anterior wall thickness (%) 64.4 7.5 39.5 4.5† 54.6 5‡
LV diastolic dimension (mm) 8.0 0.2 10.5 0.3* 8.6 0.3‡
LV systolic dimension (mm) 5.1 0.2 7.7 0.4* 6.2 0.3†‡
Endocardial fractional shortening (%) 36.7 1.3 24.2 1.2† 31.0 0.8‡
Midwall fractional shortening (%) 21.1 1.3 14.5 1.1 17.6 0.6
LV mass (g) 0.92 0.1 1.38 0.2* 1.09 0.1‡
LV mass/body weight (mg/g) 1.5 0.1 2.3 0.1* 1.8 0.3‡
Values are mean  SE. Each group represents 5 rats.
*P  .01 versus sham operation group.
†P  .05 versus sham operation group.
‡P  .05 versus MI plus medium group.
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ure 6, C) and cardiac TnI (Figure 6, F) were found in the
cell-transplanted specimens, but only a limited number of
sections were studied. These data suggest that engrafted
embryonic stem cells not only survived in myocardium as
long as 32 weeks after MI induction and cell transplantation
but also differentiated into mature cardiomyocytes.
To examine whether transplanted embryonic stem cells
induced an angiogenetic effect in injured myocardium, the
density of blood vessels was calculated in the infarcted area
with hematoxylin and eosin staining. The number of capil-
laries increased significantly (P  .01) after 32 weeks in
injured myocardium in rats with embryonic stem cell trans-
plantation relative to medium injection (Figure 7). This
result indicates that engrafted embryonic stem cells may
cause or enhance neovascularization in injured myocar-
dium.
Discussion
The major observation of this study was the improvement in
cardiac function after 32 weeks in rats that received trans-
planted embryonic stem cells. Several studies have shown
that transplantation of neonatal cardiomyocytes, fetal cardi-
omyocytes, and adult bone marrow cells can regenerate
myocardium in scar or infarcted tissue and improve cardiac
function in experimental animal models.4-9 Electron micros-
copy has revealed that nascent intercalated disks may be
formed in injured myocardium between engrafted cardio-
myocytes and host cells.10 Koh and coworkers19 further
Figure 3. Representative echocardiographic recordings in rat with sham operation (Sham), rat with MI and
injection of cell-free medium (MIMedium), and rat with MI and transplantation of embryonic stem cells (MIES
Cells). Anterior and posterior walls were thinned and hypokinetic, whereas LV cavity became dilated in rat heart
with injection of cell-free medium. In contrast, embryonic stem cell transplantation improved ventricular wall
contractility and reduced LV dilation relative to hearts with MI and injection of cell-free medium.
Figure 4. GFP-positive spots and single cells from myocardium with MI plus cell transplantation. A, Under
fluorescent microscopy (original magnification 200), frozen section shows strong GFP-positive tissue in cell-
implanted myocardium at 32 weeks after MI induction and cell transplantation. B, Single GFP-positive cells
isolated from heart with MI were verified under fluorescent microscopy (original magnification 200). Thirty-two
weeks previously heart had MI induced and was transplanted with embryonic stem cells. C, This panel
corresponds to panel B and shows host and GFP-positive cardiomyocytes under phase-contrast microscopy. Both
GFP-negative and GFP-positive cells were rod shaped with clear striations (original magnification 200). Insets
in B and C are enlargements of areas indicated by arrows.
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confirmed gap junctions between engrafted cells and host
myocytes. However, no data have shown the optimal cell
type for cell therapy in the heart. Cardiomyogenic cells
derived from embryonic stem cells may be a viable source
for cell transplantation. Embryonic stem cells have been
shown to differentiate spontaneously into the derivatives of
all three primary germ layers20 and to retain the ability to
differentiate into most cell types of the body, including
cardiomyocytes.12 Furthermore, embryonic stem cells cul-
tured within embryonic bodies can reproduce highly spe-
cialized phenotypes of cardiac tissue.21 In our study, en-
grafted embryonic stem cells survived in injured
myocardium.
Our previous13 study showed that transplanted embry-
onic stem cells could differentiate into cardiomyocytes and
subsequently enhance ventricular function at 6 weeks after
Figure 5. Engrafted embryonic stem cells are shown with hematoxylin-eosin staining in myocardium at 32 weeks
after MI and cell transplantation. A, From rat with sham operation; B, from rat with injection of cell-free medium;
C, from rat with transplantation of embryonic stem cells. Original magnification 40.
Figure 6. Immunostaining for -MHC and cardiac TnI in rat myocardium. Myocardium in sham control group was
stained positively and evenly by antibodies against -MHC (A, original magnification 200) and cardiac TnI (D,
original magnification 200). Areas in myocardium with MI and injection of cell-free medium stained positively
by antibodies against -MHC (B) and cardiac TnI (E) were smaller. In contrast, areas in MI myocardium with
transplantation of embryonic stem cells stained with antibodies against -MHC (C, original magnification 200)
and cardiac TnI (F, original magnification 200) were significantly larger.
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MI induction and cell implantation. In this study engrafted
embryonic stem cells improved cardiac function, which was
evaluated by hemodynamic and echocardiographic mea-
surements, for a much longer period. We did not perform
simultaneous pressure and volume measurements, however,
and we therefore did not evaluate load-independent indices
of ventricular function. The survival of engrafted cells in
injured myocardium was confirmed by the finding of
strongly GFP-positive tissues in myocardium at 32 weeks
after MI induction and cell transplantation. Single GFP-
positive cells isolated from hearts with embryonic stem cell
transplantation were rod shaped with clear striations. In
addition, immunostaining for -MHC and cardiac TnI
showed a higher proportion of injured myocardium with
embryonic stem cell transplantation than with medium in-
jection. Our data strongly suggest that the improvement in
cardiac function may result from transformation of cardio-
myocytes from implanted embryonic stem cells. Because
we did not evaluate enough sections in individual animals to
quantitate the extent of the engrafted embryonic stem cell
transdifferentiation, however, more experiments are cer-
tainly required. In addition, histologic examination did not
show significant evidence of immunorejection of engrafted
cells. Neither infiltration of lymphocytes and macrophages
(cell-mediated immunoreaction) nor antibody-mediated
vascular damage was observed in hearts at 32 weeks after
MI induction and cell transplantation. The underlying
mechanism of the weak immunorejection has not been
determined. A possible explanation is that the small quan-
tity of transplanted embryonic stem cells may not be able to
trigger an immunorejection, because embryonic stem cells
express few membrane surface antigens.22 From our previ-
ous experiments,23 we learned that the surface membrane of
human embryonic kidney cells does not express CD4 and
CD8, which are crucial for immunoreaction. Additional
experiments are surely required to understand the lack of
immunorejection in animals transplanted with embryonic
stem cells. Furthermore, we cannot be certain whether re-
jection reduced the beneficial effects of embryonic stem cell
transplantation because of deficiencies in quantitative as-
sessment of the extent of rejection.
Single cardiomyocytes showed that 11.9% of enzymati-
cally isolated cells from LVs in the rats at 32 weeks after MI
induction and cell transplantation were GFP positive. This
percentage is greater than that in rats at 6 weeks after MI
and cell transplantation (7.3%).13 However, the functional
improvements were similar in the rats at 6 and 32 weeks
after MI and cell transplantation. This result suggests that
the improvement of cardiac function reached a limited level
after transplantation of a certain amount of embryonic stem
cells. Damaged myocardial regions with enriched grafted
cells were accompanied by new blood vessels found in our
experiments, thus an angiogenetic effect may be crucial to
the survival of transplanted cells. New blood supply to
damaged myocardium may provide nutrition to implanted
cells, allow an avenue for removal of cellular debris during
primary injury, and also rescue some host myocytes injured
in the ischemic area. These effects may help the heart to
improve its function. The mechanism of the angiogenetic
effect caused by embryonic stem cell transplantation re-
mains to be determined. However, it is possible that trans-
planted embryonic stem cells may deliver strong signals,
Figure 7. Numeric densities of capillaries (vessels/0.2 mm2) in myocardium from sham control group (Sham), MI
plus medium group (MIMedium), and MI plus embryonic stem cells group (MIES Cells) at 32 weeks after MI
induction. In hearts with MI, embryonic stem cell transplantation significantly increased capillary density relative
to injection of cell-free medium. Double asterisk indicates P < .01 versus sham control group; double crosshatch
indicates P < .01 versus MI plus medium group.
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such as endothelial growth factors and insulinlike growth
factors, to stimulate neovascularization in the surrounding
tissues or that a portion of the implanted embryonic stem
cells may transdifferentiate into the cell sources for revas-
cularization. It has been reported that embryonic stem cells
express vascular endothelial growth factors and cause an
angiogenetic effect after cell implantation in infarcted myo-
cardium.24 In rat experiments of myocardial cryoinjury,
Tomita and associates3 counted capillary density and found
that the number of capillaries was significantly greater in
rats with transplantation of autologous bone marrow cells
than in control animals. Neovascularization therefore may
result in a reduction in infarct size of the heart, as shown by
this study.
In summary, transplantation of embryonic stem cells
caused a long-term improvement of heart function in rats
after MI. This improvement may have resulted from trans-
formation of cardiac myocytes and blood vessels by en-
grafted embryonic stem cells. This novel approach may
offer insight into potential clinical therapy for MI and heart
failure.
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